Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD) are closely related neurodegenerative disorders that share the common pathological feature of Lewy body formation. Understanding their similarities and differences is crucial for diagnosis, treatment, and research.
flowchart TD
subgraph Common_Pathology
AS"Alpha-Synuclein" --> M1"Misfolding"
M1 --> O"Oligomers"
O --> F"Preformed Fibrils"
F --> LB"Lewy Bodies"
end
subgraph DLB_Features
LB --> C1"Cortical Spread"
LB --> C2"Cognitive Decline"
C1 --> C3"Visual Hallucinations"
C1 --> C4"Cognitive Fluctuations"
end
subgraph PD_Features
LB --> P1"Brainstem Start"
P1 --> P2"Motor Symptoms"
P1 --> P3"Dopaminergic Loss"
P2 --> P4"Tremor/Bradykinesia"
end
AS -->|"Shared"| RBD"REM Sleep Behavior Disorder"
AS -->|"Shared"| AUT"Autonomic Dysfunction"
| Feature |
Dementia with Lewy Bodies (DLB) |
Parkinson's Disease (PD) |
| Prevalence |
~1.4 million (US) |
~1 million (US) |
| Core Feature |
Dementia with Lewy bodies |
Motor symptoms with Lewy bodies |
| Primary Symptom |
Cognitive fluctuations, visual hallucinations |
Tremor, bradykinesia, rigidity |
| Onset Age |
50-80 years (median ~75) |
50-80 years (median ~60) |
| Lewy Body Distribution |
Cortical and subcortical |
Initially brainstem, spreads later |
DLB:
- Progressive cognitive decline interfering with daily activities
- Core features:
- Visual hallucinations (typically early, detailed)
- Spontaneous parkinsonism
- Cognitive fluctuations
- REM sleep behavior disorder
- Suggestive features:
- Low dopamine transporter uptake in basal ganglia
- Polysomnographic confirmation of REM sleep without atonia
PD:
- Must have bradykinesia PLUS at least one:
- Resting tremor
- Rigidity
- Postural instability
- Additional non-motor symptoms:
- Sleep disorders (RBD)
- Autonomic dysfunction
- Olfactory loss
- Depression
| Feature |
DLB |
Parkinson's Disease |
| Cognitive Onset |
Early (within 1 year of motor symptoms) |
Late (after motor symptoms) |
| Motor Symptoms |
Present but variable |
Core feature |
| Visual Hallucinations |
Core feature, early |
Often later, often drug-induced |
| Cognitive Fluctuations |
Core feature |
Less prominent |
| Autonomic Dysfunction |
Severe, early |
Present, progressive |
| Treatment Response |
Poor to dopaminergic drugs |
Good initially |
| Neuroleptic Sensitivity |
High (>50%) |
Moderate |
¶ Lewy Body Distribution
| Brain Region |
DLB |
PD (early) |
PD (advanced) |
| Substantia Nigra |
+++ |
+++ |
+++ |
| Locus Coeruleus |
+++ |
++ |
+++ |
| Dorsal Raphe |
++ |
++ |
+++ |
| Basal Forebrain |
+++ |
+ |
++ |
| Cortex |
+++ (temporal, parietal) |
- |
++ |
| Hippocampus |
++ |
- |
+ |
| Pathology |
DLB |
PD |
| Alpha-synuclein |
Lewy bodies, Lewy neurites |
Lewy bodies |
| Amyloid-beta |
Present in ~50% |
Usually absent |
| Tau |
Variable, sparse |
Usually absent |
| Neurotransmitter |
DLB |
PD |
PDD |
| Dopamine |
++ |
+++ |
++ |
| Acetylcholine |
+++ (severe) |
+ |
++ |
| Serotonin |
++ |
++ |
++ |
| Norepinephrine |
+++ |
++ |
++ |
| Gene |
Effect |
Evidence |
| SNCA |
Multiplications, mutations |
Strong |
| GBA |
N370S, L444P |
Strong |
| APOE |
ε4 allele |
Moderate |
| SNCA |
Rep1 risk allele |
Moderate |
| BIN1 |
Risk variants |
Moderate |
| Gene |
Effect |
Evidence |
| LRRK2 |
G2019S |
Strong (CA) |
| SNCA |
A53T, A30P |
Strong (CA) |
| PARKIN |
Recessive mutations |
Strong (AR) |
| PINK1 |
Recessive mutations |
Strong (AR) |
| GBA |
N370S |
Strong risk |
| VPS35 |
D620N |
Strong (CA) |
- SNCA: Both DLB and PD involve alpha-synuclein aggregation
- GBA: Glucocerebrosidase mutations increase risk for both
- APOE ε4: Risk factor for both, stronger in DLB
| Treatment |
DLB |
PD |
PDD |
| Levodopa |
Variable response |
First-line |
Limited benefit |
| Dopamine Agonists |
Use with caution |
First-line |
Limited |
| Cholinesterase Inhibitors |
First-line (e.g., rivastigmine) |
Limited |
First-line |
| Memantine |
May help |
Not used |
May help |
| Clonazepam |
For RBD |
Not used |
For RBD |
| Antipsychotics |
AVOID (severe sensitivity) |
Use with caution |
AVOID |
| Symptom |
DLB Management |
PD Management |
| RBD |
Clonazepam, melatonin |
Clonazepam, melatonin |
| Depression |
SSRIs (cautiously) |
SSRIs, SNRIs |
| Autonomic |
Supportive care |
Supportive care |
| Olfactory |
No treatment |
Limited treatments |
DLB and PD are now recognized as part of a disease spectrum:
PD without dementia -----> PD with dementia (PDD)
|
| (overlapping)
|
DLB
"1-year rule":
- DLB: Cognitive impairment within 1 year of motor symptoms
- PDD: Cognitive impairment develops >1 year after motor symptoms
Note: This distinction is increasingly viewed as arbitrary, as both conditions have significant overlap.
| Target |
DLB |
PD |
| Alpha-synuclein |
Immunotherapy, aggregation inhibitors |
Immunotherapy, gene therapy |
| Neuroinflammation |
CSF1R inhibitors |
TREM2 agonists |
| Autophagy |
mTOR inhibitors, autophagy enhancers |
LRRK2 inhibitors |
DLB has historically been understudied compared to PD and AD. Recent interest in alpha-synuclein targeting therapies may benefit both conditions.